Finasteride and Sexual Side Effects: Rates, Reversibility and PFS

In the registration trials for oral finasteride at the hair-loss strength, sexual side effects — reduced libido, erectile difficulty, ejaculation disorder — were reported by about 3.8% of men on finasteride and 2.1% on placebo. The difference, around 1.7 percentage points, is the excess attributable to the drug. Most cases resolved during continued treatment or after stopping.

Two things about those numbers. First, the placebo rate matters: about one man in fifty on a sugar pill reported the same problems, which is a measure of how much expectation and ordinary life contribute. A man who starts finasteride having read that it will ruin his sex life is more likely to report that it has — the nocebo effect is real and has been demonstrated specifically for this drug. Second, the trials were designed to detect efficacy, not rare persistent harms, and they followed men for a year or two. They cannot rule out an uncommon effect that lasts.

That is where the contested part begins. Since the mid-2000s a number of men have reported sexual, cognitive and mood symptoms that began on finasteride and persisted — for months, years, or indefinitely — after stopping it. The cluster has a name, post-finasteride syndrome, a foundation, and a place in the regulatory record: the FDA added persistent sexual dysfunction to the label in 2012, and European regulators have since added suicidal ideation.

What is not settled is how common it is, or whether the drug causes it in the way the name implies. The reported cases are real; the mechanism is unproven; controlled studies have found it hard to distinguish a drug effect from the base rate of sexual and mood problems in the population, and from the nocebo dynamics above. Expert bodies describe the evidence as inconclusive, which is the honest word. It is neither a myth nor an established syndrome.

Our position: the possibility is disclosed to every man before he starts, the symptoms are asked about at every review, and any persistent problem is a reason to stop and not restart. We do not tell men it cannot happen. We do not tell them it is likely.

The 4-in-1 treatment is topical, and the reasoning is sound: applied to the scalp, finasteride reduces DHT in the scalp with much less reaching the bloodstream, and the trials of topical products show a smaller drop in systemic DHT than the tablet. The expectation was fewer sexual side effects, and that is probably true on average.

But it is not zero, and in April 2025 the FDA issued an alert on compounded topical finasteride products — including combinations with minoxidil, which is what most topical hair products are. The agency had received reports of erectile dysfunction, reduced libido, testicular pain, anxiety, depression and suicidal thoughts in men using them, and noted that in most of the reports the problems persisted after the product was stopped. The alert also flagged the risk of transfer to others, particularly women, through contact with treated skin.

The numbers are small — dozens of reports over several years against a very large number of users — and reports are not rates. But the alert ended the idea that "topical" means "no systemic effect," and it applies directly to products like ours.

A man with a current or recent mood disorder, particularly depression, is a man for whom the psychiatric signal — however uncertain — changes the balance, and for whom we would want the prescribing clinician for that condition involved. A man with existing sexual difficulty should have it assessed first — see erectile difficulty as a heart signal — rather than adding a drug that may complicate it. A man planning a family in the near term should know that finasteride affects semen parameters and that the topical product can transfer.

And a man who, having read this page, would rather not take the risk has made a reasonable decision. Hair loss is not a disease. The hair-thinning page covers what else there is.